Lead program
CIN-111 Best-in-class AGT siRNA for hypertension
Pipeline
CIN-111
AGT siRNA · Hypertension
Phase I — A single ascending dose study is ongoing.
In hypertensive non-human primates, CIN-111 achieved nearly 100 percent reduction in AGT protein at one month, sustained with a mean of approximately 88 percent reduction on Day 119. CIN-111 reduced systolic blood pressure to below 120 mmHg from Day 42 onward, with no significant rebound trend by Day 119, and outperformed Roche’s zilebesiran at the same dose.
CIN-111 has demonstrated roughly a 100-fold therapeutic window with an excellent safety profile in GLP toxicology studies. Together, these data support a long-acting profile with infrequent administration. The IP estate for CIN-111 is global, pending in major markets, with expected expiry in 2044.
- ~100×
- therapeutic window in GLP toxicology
- ~88%
- mean AGT reduction sustained to Day 119 in hypertensive NHPs
- 2044
- expected IP expiry, global and pending in major markets
Clinical development
A single ascending dose study is ongoing.
- Design
- Single-dose, single ascending dose (SAD)
- Population
- Patients with mild-to-moderate hypertension
- Washout
- 2-week washout of concomitant antihypertensives before dosing
- Assessments
- Safety, PK, PD (AGT and blood pressure), and immunogenicity
- Randomization
- 3:1 (CIN-111 : placebo)
- Cohorts
- 8 subjects, expandable to 24 when a dose yields >80% AGT reduction at Day 28